Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 9Genitourinary 1

Conditions

Prostatic Neoplasms 5016Carcinoma, Renal Cell 1574Urinary Bladder Neoplasms 1279Kidney Neoplasms 723Breast Neoplasms 642Neoplasms 628Carcinoma, Transitional Cell 487Neoplasm Metastasis 468Carcinoma, Non-Small-Cell Lung 467Melanoma 421Ovarian Neoplasms 399Colorectal Neoplasms 370Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 231Stomach Neoplasms 226Uterine Cervical Neoplasms 223Testicular Neoplasms 215Non-Muscle Invasive Bladder Neoplasms 214Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 187Colonic Neoplasms 167Carcinoma, Hepatocellular 165Esophageal Neoplasms 164Endometrial Neoplasms 164Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 128Neuroblastoma 127Small Cell Lung Carcinoma 125

Interventions

Prednisone 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hyperaldosteronism × Genitourinary × Clear all
NCT01867710 2019-07-05

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Janssen Pharmaceutica N.V., Belgium

Phase 2 Completed
164 enrolled 22 charts
Genitourinary

Hyperaldosteronism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡